Late Onset Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter spp.: Experience with Tigecycline
Authors:
- D. CurcioDCD. Curcio
- F. FernándezFFF. Fernández
- J. VergaraJVJ. Vergara
- W. VazquezWVW. Vazquez
- C.M. LunaCLC.M. Luna
- 1 February 2009
- journal article
- clinical trial
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 21 (1) , 58-62
Abstract
The aim of the study was to evaluate the clinical success rate of 73 patients with ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR)-Acinetobacter spp. treated with tigecycline in seven intensive Care Units in Argentina and to determine which predictor variables were significant in this context. Clinical success in our patients was 69.86% (Ci= 58.65-81.07%) 51/73, without significant differences between patients with VAP due to MDR-Acinetobacter spp. carbapenem-susceptible or carbapenem-resistant and only susceptible to colistin, minocyline and tigecycline (70% 44/73 vs. 69% 29/73 respectively, p=0.9006), and between patients who received 48h of prior antibiotics (73.3% 22/30 vs 67.4% 29/43 respectively, p=0.7791). Age >67 and using other method than BAL for respiratory sampling were identified as predicting variables for negative clinical outcome. Our results suggest that tigecycline may be an acceptable alternative for therapy in patients with VAP caused by MDR-Acinetobacter spp. Nevertheless, only controlled clinical trials will provide the evidence to support approval for new indications.Keywords
This publication has 9 references indexed in Scilit:
- In vitro activities of ‘new’ and ‘conventional’ antibiotics against multidrug resistant Gram negative bacteria from patients in the intensive care unitPathology, 2007
- Uso inicial de tigeciclina en ArgentinaRevista chilena de infectología, 2007
- Early Experience with Tigecycline for Ventilator‐Associated Pneumonia and Bacteremia Caused by Multidrug‐Resistant Acinetobacter baumanniiPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
- In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumanniiJournal of Antimicrobial Chemotherapy, 2007
- Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infectionsThe Lancet Infectious Diseases, 2006
- TigecyclineJournal of Antimicrobial Chemotherapy, 2005
- Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecyclineInternational Journal of Antimicrobial Agents, 2005
- Performance of the Mortality Probability Models in assessing severity of illness during the first week in the intensive care unitCritical Care Medicine, 2000
- Mortality Probability Models (MPM II) Based on an International Cohort of Intensive Care Unit PatientsJAMA, 1993